PRimary IndividualiZed Evaluation of Cardiovascular Events in Patients With Diabetes Mellitus Using hemoTAG

Part of paid clinical trials in West Palm Beach, Florida.

Sponsor
Aventusoft, LLC.
Study ID
NCT06567795
Status
Recruiting
Apply to this trial

Conditions

Eligibility Criteria

Sex
ALL
Age
40 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • Hemotag — DEVICE
    Hemotag non-invasive medical device is used to see cardiac function for DM2 patients at-home for 30 days

Study Details

To evaluate the proportion of diabetic mellitus patients with CV events as measured by HEMOTAG.

Key Dates

Start date
Mar 14, 2024
Status verified
Aug 2024
Primary completion
Mar 18, 2026
Completion
Mar 18, 2027

Study Design

Enrollment
189 participants (estimated)

Arms

  • Arm: HEMOTAG with Standard of Care in DM patients
    HEMOTAG with Standard of Care: To evaluate the proportion of diabetic mellitus patients with cardiovascular events as identified by HEMOTAG measurements over a 12 month duration.

Primary Outcome Measure

To evaluate the proportion of diabetic mellitus patients with cardiovascular events as identified by HEMOTAG measurements over a 12 month duration. [ Time Frame: 12 months ]

Central Contacts

Locations (1)

FacilityCityStateZIPSite coordinators
Metabolic Research Institute, IncWest Palm BeachFlorida33401'
Alayzah Garcia, BA
[email protected]
561-802-3060
Barry Horowitz, MD (PRINCIPAL_INVESTIGATOR)

Find similar trials in West Palm Beach, FL

By condition
Peripheral artery disease
By specialty
CardiologyVascular medicine
By research site
Metabolic Research Institute, Inc· West Palm Beach, FL

Related Studies